DelveInsight’s Acute lymphoblastic leukemia (ALL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Acute lymphoblastic leukemia (ALL) for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Acute lymphoblastic leukemia (ALL) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Acute lymphoblastic leukemia (ALL) till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Acute lymphoblastic leukemia (ALL) market.
• Identifying patient populations in the global “Acute lymphoblastic leukemia (ALL) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Acute lymphoblastic leukemia (ALL) therapeutics in each of the markets covered.
• To understand the future market competition in the global Acute lymphoblastic leukemia (ALL) therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2023.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Acute lymphoblastic leukemia (ALL) for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
Note: This report requires 7-10 business days to complete.
'
Table of Contents
• Acute lymphoblastic leukemia (ALL) overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Acute lymphoblastic leukemia (ALL) Market
• Global Epidemiology of Acute lymphoblastic leukemia (ALL) Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Acute lymphoblastic leukemia (ALL) Drug Sales (USD Millions)
• Table 6: Global Epidemiology of Acute lymphoblastic leukemia (ALL) (2013-2023)
• Table 7: Acute lymphoblastic leukemia (ALL) Global Market (USD Millions), (2013-2015)
• Table 8: Acute lymphoblastic leukemia (ALL) Global Market (USD Millions), (2016-2023)
• Table 9: Acute lymphoblastic leukemia (ALL) US Market (USD Millions), (2013-2015)
• Table 10: Acute lymphoblastic leukemia (ALL) US Market (USD Millions), (2016-2023)
• Table 11: Acute lymphoblastic leukemia (ALL) Germany Market (USD Millions), (2013-2015)
• Table 12: Acute lymphoblastic leukemia (ALL) Germany Market (USD Millions), (2016-2023)
• Table 13: Acute lymphoblastic leukemia (ALL) United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Acute lymphoblastic leukemia (ALL) United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Acute lymphoblastic leukemia (ALL) France Market (USD Millions), (2013-2015)
• Table 16: Acute lymphoblastic leukemia (ALL) France Market (USD Millions), (2016-2023)
• Table 17: Acute lymphoblastic leukemia (ALL) Italy Market (USD Millions), (2013-2015)
• Table 18: Acute lymphoblastic leukemia (ALL) Italy Market (USD Millions), (2016-2023)
• Table 19: Acute lymphoblastic leukemia (ALL) Spain Market (USD Millions), (2013-2015)
• Table 20: Acute lymphoblastic leukemia (ALL) Spain Market (USD Millions), (2016-2023)
• Table 21: Acute lymphoblastic leukemia (ALL) Japan Market (USD Millions), (2013-2015)
• Table 22: Acute lymphoblastic leukemia (ALL) Japan Market (USD Millions), (2016-2023)
• Table 23: Acute lymphoblastic leukemia (ALL) ROW Market (USD Millions), (2013-2015)
• Table 24: Acute lymphoblastic leukemia (ALL) ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Acute lymphoblastic leukemia (ALL) Drug Sales (USD Millions)
• Figure 2: Global Epidemiology of Acute lymphoblastic leukemia (ALL) (2013-2023)
• Figure 3: Acute lymphoblastic leukemia (ALL) Global Market (USD Millions), (2013-2015)
• Figure 4: Acute lymphoblastic leukemia (ALL) Global Market (USD Millions), (2016-2023)
• Figure 5: Acute lymphoblastic leukemia (ALL) US Market (USD Millions), (2013-2015)
• Figure 6: Acute lymphoblastic leukemia (ALL) US Market (USD Millions), (2016-2023)
• Figure 7: Acute lymphoblastic leukemia (ALL) Germany Market (USD Millions), (2013-2015)
• Figure 8: Acute lymphoblastic leukemia (ALL) Germany Market (USD Millions), (2016-2023)
• Figure 9: Acute lymphoblastic leukemia (ALL) United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Acute lymphoblastic leukemia (ALL) United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Acute lymphoblastic leukemia (ALL) France Market (USD Millions), (2013-2015)
• Figure 12: Acute lymphoblastic leukemia (ALL) France Market (USD Millions), (2016-2023)
• Figure 13: Acute lymphoblastic leukemia (ALL) Italy Market (USD Millions), (2013-2015)
• Figure 14: Acute lymphoblastic leukemia (ALL) Italy Market (USD Millions), (2016-2023)
• Figure 15: Acute lymphoblastic leukemia (ALL) Spain Market (USD Millions), (2013-2015)
• Figure 16: Acute lymphoblastic leukemia (ALL) Spain Market (USD Millions), (2016-2023)
• Figure 17: Acute lymphoblastic leukemia (ALL) Japan Market (USD Millions), (2013-2015)
• Figure 18: Acute lymphoblastic leukemia (ALL) Japan Market (USD Millions), (2015-2023)
• Figure 19: Acute lymphoblastic leukemia (ALL) ROW Market (USD Millions), (2013-2015)
• Figure 20: Acute lymphoblastic leukemia (ALL) ROW Market (USD Millions), (2016-2023)
• Amgen Inc.
• Ariad Pharmaceuticals, Inc.
• GlaxoSmithKline Plc.
• Baxalta Incorporated
• Constellation Pharmaceuticals, Inc.
• Bio-Path Holdings, Inc.
• EpiZyme, Inc.
• Bristol-Myers Squibb Company
• Array BioPharma Inc.
• AstraZeneca Plc
• Atara Biotherapeutics, Inc.
• Bellicum Pharmaceuticals, Inc.
• Bexion Pharmaceuticals, LLC.
• BioSight Ltd.
• Calithera Biosciences, Inc.
